reported a more subtle effect with decreased cell invasion and no effect on proliferation or survival, highlighting that CSF-1R inhibition therapeutic effects may depend on the glioma subtype (proneural vs mesenchymal). This evidence concerns the gene CSF1R and central nervous system cancer.